The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Population-based evaluation of second-line palliative chemotherapy (SCT) versus erlotinib (E) in advanced non-small cell lung cancer (NSCLC) patients (pts).
Krista Noonan
No relevant relationships to disclose
Cheryl Ho
Research Funding - Lilly; Roche
Sophie Sun
No relevant relationships to disclose
Barbara L. Melosky
No relevant relationships to disclose
Janessa J. Laskin
No relevant relationships to disclose
Nevin Murray
No relevant relationships to disclose